CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS ...

CVS Caremark is adding Zepbound, Eli Lilly’s obesity drug, back to its commercial insurance plan formularies, more than a ...

Despite a more flexible administration profile, Foundayo generated lower first-month prescribing rates than the Wegovy Pill ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

Add Yahoo as a preferred source to see more of our stories on Google. Wegovy, a weight-loss drug that helps people slim down, is bulking up for its first appearance in the Super Bowl. Novo Nordisk, ...

If you’re weighing the option of Wegovy versus Zepbound for weight loss, here’s how the two medications compare in terms of ...

In a letter sent last week, the US Food and Drug Administration (FDA) said that a TV ad for Novo Nordisk's Wegovy (semaglutide) tablets misleads consumers into thinking the pill is better than other ...

Despite reaching multiyear lows earlier this year due to a disappointing outlook, Novo Nordisk (NVO) is closing the gap with its main rival, Eli Lilly (LLY), with shares of the Danish drugmaker adding ...

Novo hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales, saying it now expects ...

Pharmac has put Wegovy on its list of medicines suitable for future funding.

Private Medicare plans that pay for prescription drugs can now cover obesity medicine Wegovy, if it's prescribed to reduce the risk of heart attacks and strokes in people at high risk. For the first ...